Summary:
- This article reports the results of a phase 3 clinical trial evaluating the efficacy and safety of inebilizumab, a monoclonal antibody, in the treatment of IgG4-related disease (IgG4-RD).
- The study found that inebilizumab was more effective than placebo in achieving a primary endpoint of a clinical response at week 24, defined as a reduction in the IgG4-RD Responder Index (RI) score of at least 2 points from baseline.
- Inebilizumab was generally well-tolerated, with a safety profile consistent with previous studies, indicating it may be a promising new treatment option for patients with IgG4-RD.